IRF9 and cancer: Our results demonstrated that the increased gene expression of IRF9, a member of the IRF/STAT family, serves as a biomarker for the responsiveness to these DNA-damaging chemotherapies and suggest that its suppression may be a mechanism by which cancer cells acquire PARP inhibitor resistance.